Page 18 - Compass Pathways News Today

A group of former professional athletes traveled to Jamaica to try psychedelics as a way to help cope with the aftereffects of concussions and a career of body-pounding injuries. Will this still largely untested treatment work?

The boxer felt broken. Every day, he was waking up in pain. Some days, it was debilitating headaches. Other times, it was his back. Or his fists. His ribs. His nose. On top of that, he had mood swings. Depression. Anxiety.

COMPASS Pathways plc (NASDAQ:CMPS – Get Rating) was the target of a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 4,270,000 shares, a drop of 6.4% from the March 15th total of 4,560,000 shares. Based on an average trading volume of 305,200 shares, the […]

Atai's stock is hurting, but its pipeline is still packed with promising programs.

LONDON, April 10, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to...

The Johns Hopkins University professor has been a pioneer in the field of psychedelic research. Approaching the end of his life, he’s launching a new project that he hopes might help save the world.

The company's co-founder and chairman increased his position and explained why.

We can rail against the corporate water that’s flooding the psychedelic ship—or we can all grab a bucket and start bailing.

To strip psychedelic use down to its chemicals is to de-radicalize its communal and anti-authoritarian roots.

Just like marijuana a decade ago, ketamine has become more popular for medical uses — and a growing number of businesses are embracing the drug recreationally known as "Special K.”